Literature DB >> 23549023

Clonal analysis of human anti-V3 monoclonal antibodies selected by a V3 tetramer.

Liuzhe Li1, Xiao-Hong Wang, Sagarika Banerjee, Barbara Volsky, Constance Williams, M Anthony Moody, Susan Zolla-Pazner, Miroslaw K Gorny.   

Abstract

The production of human monoclonal antibodies (mAbs) has been improved recently using the single B cell and PCR technology. A number of new anti-HIV-1 mAbs directed to various epitopes were produced by selecting single B cells from HIV positive individuals using the HIV-1 envelope (Env) proteins, and we tested whether the peptide can select B cells specific to a particular Env epitope. Using the fluorescently-labeled peptide tetramer representative of the V3 loop of HIV-1 Env gp120 for staining the B cells derived from one HIV-1 infected donor, four clonal human mAbs were produced with specificity to the V3 region. The clonality of the four V3 mAbs was based on the usage of the same immunoglobulin genes and almost identical sequence of CDRs. The amino acid changes were present only in the framework and, possibly, they could be related to the differences observed in the relative affinity binding of these four mAbs to V3 antigen. One representative V3 mAb displayed very potent neutralizing activity to one of two viruses tested. This study shows the feasibility of utilizing a peptide tetramer to select epitope-specific B cells and produce mAbs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23549023      PMCID: PMC3708495          DOI: 10.3233/HAB-130264

Source DB:  PubMed          Journal:  Hum Antibodies        ISSN: 1093-2607


  23 in total

1.  Identification of an antigen-specific B cell population.

Authors:  Jeffrey Newman; Jeffrey S Rice; Chuansheng Wang; Shannon L Harris; Betty Diamond
Journal:  J Immunol Methods       Date:  2003-01-15       Impact factor: 2.303

2.  Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies.

Authors:  Michael S Seaman; Holly Janes; Natalie Hawkins; Lauren E Grandpre; Colleen Devoy; Ayush Giri; Rory T Coffey; Linda Harris; Blake Wood; Marcus G Daniels; Tanmoy Bhattacharya; Alan Lapedes; Victoria R Polonis; Francine E McCutchan; Peter B Gilbert; Steve G Self; Bette T Korber; David C Montefiori; John R Mascola
Journal:  J Virol       Date:  2009-11-25       Impact factor: 5.103

3.  Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes.

Authors:  Catarina E Hioe; Terri Wrin; Michael S Seaman; Xuesong Yu; Blake Wood; Steve Self; Constance Williams; Miroslaw K Gorny; Susan Zolla-Pazner
Journal:  PLoS One       Date:  2010-04-21       Impact factor: 3.240

4.  Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity.

Authors:  John Pietzsch; Johannes F Scheid; Hugo Mouquet; Michael S Seaman; Christopher C Broder; Michel C Nussenzweig
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

5.  Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.

Authors:  Johannes F Scheid; Hugo Mouquet; Beatrix Ueberheide; Ron Diskin; Florian Klein; Thiago Y K Oliveira; John Pietzsch; David Fenyo; Alexander Abadir; Klara Velinzon; Arlene Hurley; Sunnie Myung; Farid Boulad; Pascal Poignard; Dennis R Burton; Florencia Pereyra; David D Ho; Bruce D Walker; Michael S Seaman; Pamela J Bjorkman; Brian T Chait; Michel C Nussenzweig
Journal:  Science       Date:  2011-07-14       Impact factor: 47.728

6.  HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages.

Authors:  M Anthony Moody; Nicole L Yates; Joshua D Amos; Mark S Drinker; Joshua A Eudailey; Thaddeus C Gurley; Dawn J Marshall; John F Whitesides; Xi Chen; Andrew Foulger; Jae-Sung Yu; Ruijun Zhang; R Ryan Meyerhoff; Robert Parks; Julia Cavanaugh Scull; Lu Wang; Nathan A Vandergrift; Joy Pickeral; Justin Pollara; Garnett Kelsoe; S Munir Alam; Guido Ferrari; David C Montefiori; Gerald Voss; Hua-Xin Liao; Georgia D Tomaras; Barton F Haynes
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

7.  Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.

Authors:  Maxim Totrov; Xunqing Jiang; Xiang-Peng Kong; Sandra Cohen; Chavdar Krachmarov; Aidy Salomon; Constance Williams; Michael S Seaman; Ruben Abagyan; Timothy Cardozo; Miroslaw K Gorny; Shixia Wang; Shan Lu; Abraham Pinter; Susan Zolla-Pazner
Journal:  Virology       Date:  2010-07-21       Impact factor: 3.616

8.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

9.  Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting.

Authors:  Lynn Morris; Xi Chen; Munir Alam; Georgia Tomaras; Ruijun Zhang; Dawn J Marshall; Bing Chen; Robert Parks; Andrew Foulger; Frederick Jaeger; Michele Donathan; Mira Bilska; Elin S Gray; Salim S Abdool Karim; Thomas B Kepler; John Whitesides; David Montefiori; M Anthony Moody; Hua-Xin Liao; Barton F Haynes
Journal:  PLoS One       Date:  2011-09-30       Impact factor: 3.240

10.  Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infected subject.

Authors:  Liuzhe Li; Xiao-Hong Wang; Sagarika Banerjee; Barbara Volsky; Constance Williams; Diana Virland; Arthur Nadas; Michael S Seaman; Xuemin Chen; Paul Spearman; Susan Zolla-Pazner; Miroslaw K Gorny
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

View more
  4 in total

1.  Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.

Authors:  Ann J Hessell; Sean McBurney; Shilpi Pandey; William Sutton; Lily Liu; Liuzhe Li; Maxim Totrov; Susan Zolla-Pazner; Nancy L Haigwood; Miroslaw K Gorny
Journal:  Vaccine       Date:  2016-04-19       Impact factor: 3.641

2.  B Cell Tetramer Development for Veterinary Vaccinology.

Authors:  Michael C Rahe; Kevin L Gustafson; Michael P Murtaugh
Journal:  Viral Immunol       Date:  2017-07-31       Impact factor: 2.257

3.  Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL.

Authors:  Rajnish Kumar; Ruimin Pan; Chitra Upadhyay; Luzia Mayr; Sandra Cohen; Xiao-Hong Wang; Preetha Balasubramanian; Arthur Nádas; Michael S Seaman; Susan Zolla-Pazner; Miroslaw K Gorny; Xiang-Peng Kong; Catarina E Hioe
Journal:  J Virol       Date:  2015-06-24       Impact factor: 5.103

4.  Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner.

Authors:  Thomas Musich; Liuzhe Li; Lily Liu; Susan Zolla-Pazner; Marjorie Robert-Guroff; Miroslaw K Gorny
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.